Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$79.12 USD

79.12
618,387

+0.73 (0.93%)

Updated May 30, 2024 04:00 PM ET

After-Market: $79.09 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Here's Why You Should Retain HealthEquity Stock for Now

Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.

HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates

HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.

HealthEquity (HQY) Q4 Earnings and Revenues Surpass Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of 14.71% and 1.36%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?

Why HealthEquity (HQY) is Poised to Beat Earnings Estimates Again

HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why HealthEquity (HQY) Might Surprise This Earnings Season

HealthEquity (HQY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

HealthEquity (HQY) Earnings Expected to Grow: Should You Buy?

HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc (TDOC) Up 49% Year to Date: Will the Rally Continue?

Teladoc (TDOC) benefits from its fast growing healthcare business and international expansion.

Sanghamitra Saha headshot

5 Top Stocks With Great Earnings Beat Potential

These top-ranked stocks are likely to beat on the bottom line in their next release.

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results

HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings

Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.

AMN vs. HQY: Which Stock Should Value Investors Buy Now?

AMN vs. HQY: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to OPKO Health Stock for Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?

Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.

Sanghamitra Saha headshot

Bet on Earnings Beat With 5 Top-Ranked Stocks

These top-ranked stocks are likely to beat on bottom line in their next releases.

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?

Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).